An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)

Trial Profile

An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2015

At a glance

  • Drugs Pixantrone (Primary) ; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 22 Oct 2009 Results will be presented at the Lymphoma and Myeloma 2009 Conference, according to a Cell Therapeutics media release.
    • 28 Jul 2006 Status change
    • 09 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top